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Bacteriocin producers normally possess dedicated immunity systems to protect themselves from their own bacteriocins. Lacto-
coccus lactis strains LMG2081 and BGBM50 are known as lactococcin G producers. However, BGBM50 was sensitive to
LMG2081, which indicated that LMG2081might produce additional bacteriocins that are not present in BGBM50. Therefore,
whole-genome sequencing of the two strains was performed, and a lantibiotic operon (called lctLMG) was identified in LMG2081
but not in BGBM50. The lctLMG operon contains six open reading frames; the first three genes, lmgA, lmgM, and lmgT, are in-
volved in the biosynthesis and export of bacteriocin, while the other three genes, lmgF, lmgE, and lmgG, are involved in lantibi-
otic immunity. Mutational analysis confirmed that the lctLMG operon is responsible for the additional antimicrobial activity.
Specifically, site-directed mutation within this operon rendered LMG2081 inactive toward BGBM50. Subsequent purification
and electrospray ionization–time of flight mass spectrometric analysis confirmed that the lantibiotic bacteriocin called lacticin
LMG is exported as a 25-amino-acid peptide. Lacticin LMG is highly similar to the lacticin 481 group. It is interesting that a bac-
teriocin producer produces two different classes of bacteriocins, whose operons are located in the chromosome and a plasmid.
Many lactic acid bacteria (LAB) have the ability to produceribosomally synthesized antimicrobial peptides or proteins,
known as bacteriocins. These proteins are antimicrobials with dif-
ferent modes of action against closely related bacterial species,
medically important pathogens, and bacteria involved in food
spoilage (1). LAB frequently found in food constitute an impor-
tant portion of our gut microbiota. Additionally, many LAB are
generally recognized as safe (GRAS) for ingestion, which is one of
the prerequisites for use as natural preservatives in foods and feeds
and as antimicrobials in the treatment of infections. Bacteriocins
produced by LAB have been studied intensively in recent years.
Bacteriocins produced by LAB are divided into two primary
classes, i.e., lantibiotics (class I) and unmodified bacteriocins
(class II) (2). Class I bacteriocins (lantibiotics) contain unusual
amino acids such as lanthionine and dehydrated amino acids, as a
result of posttranslational modifications such as dehydration of
serine and threonine and formation of lanthionine bridges. Class
II bacteriocins consist only of unmodified peptides or peptides
with minor modifications (e.g., sulfide bridges and cyclization).
Furthermore, class II bacteriocins are classified into four sub-
classes, i.e., pediocin-like bacteriocins (class IIa), two-peptide
bacteriocins (class IIb), cyclic bacteriocins (class IIc), and linear
non-pediocin-like bacteriocins (class IId) (3).
Thus far, over 95 different lantibiotics have been isolated from
Gram-positive bacteria and characterized (4). According to the
topology of their structures, lantibiotics have been classified as
type A and type B (5). Type A lantibiotics are small (2 to 5 kDa)
and can be elongated [subtype type A(I)] or contain a tail-and-
ring region [subtype type A(II)] (6). For type A(I) lantibiotics,
lanthionine and 3-methyllanthionine residues are formed by the
action of two distinct enzymes (LanB and LanC) after the dehy-
dration of serine and threonine; for type A(II) lantibiotics, in con-
trast, these residues are formed by the action of one enzyme
(LanM) (7). Furthermore, for type A(I) lantibiotics, peptides are
exported outside the cell and the leader peptide is removed by the
exporter LanT and the protease LanP (4). For type A(II) lantibi-
otics, however, both processes (i.e., leader peptide cleavage and
mature lantibiotic transport) are catalyzed by LanT (4), an ex-
porter with an N-terminal protease domain. The immunity sys-
tem of type A(II) lantibiotics is encoded and realized through the
coexpression of three genes, namely, lanF, lanE, and lanG (8). This
system of three genes ensures immunity by preventing lantibiotics
from reaching the density necessary for pore formation, which is
theirmode of action. For some lantibiotics, such as nukacin ISK-1,
the presence of two immunity systems (NukFEG and NukH) en-
hanced immunity, comparedwith the presence of only one system
(9). The expression of nukFEG genes resulted in a greater degree of
immunity than did nukH gene expression alone, which suggests
that theNukFEG system plays amajor role in immunity, while the
NukH protein most likely functions as an accessory protein. Type
B lantibiotics, such as mersacidin, cinnamycin, duramycin, and
ancovenin, are small (approximately 2 kDa), are more globular
and compact, and kill sensitive cells by interfering with cellular
enzymatic reactions such as cell wall synthesis (10).
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Nisin, a type A(I) lantibiotic, is one of the best known lantibi-
otics, with commercial applications in food processing and fer-
mentation (11). Type A(II) lantibiotics, such as lacticin 481 and
related lantibiotics, have demonstrated potential for use in food
production. Previous results showed that lacticin 481, because it is
active against LAB, can be used to speed cheese ripening by lysing
starter cultures and increasing the amounts of intracellular en-
zymes (12–14). In addition, lacticin 481 could be used to inhibit
the growth of nonstarter bacteria in cheese, which can causemajor
economic losses (15). Lacticin 481 and related lantibiotics do not
show activity against pathogenic bacteria. In some cases, however,
lacticin 481, in combination with high-pressure treatments, af-
fected the survival of Listeria monocytogenes, Staphylococcus au-
reus, and Escherichia coli O157:H7 in raw milk cheeses (16–18).
Lactococcus lactis strains LMG2081 and BGBM50 are known as
producers of lactococcin G, a class IIb bacteriocin (19, 20). In
cross-immunity tests, it was observed that strain LMG2081 inhib-
ited the growth of strain BGBM50. To determine the differences
between these two strains, whole-genome sequencing of strains
LMG2081 andBGBM50was performed.Genome analysis showed
that strain LMG2081 contains an operon for the synthesis of a
novel bacteriocin, lacticin LMG, belonging to the type A(II) class
of lantibiotics. Purification and electrospray ionization–time of
flight (ESI-TOF)mass spectrometric analysis showed that lacticin
LMG is exported as a 25-amino-acid peptide.
MATERIALS AND METHODS
Bacterial strains andplasmids.The bacterial strains and plasmids used in
this study are listed in Table 1. L. lactis LMG2081 was isolated from the
European pear (Pyrus communis). Lactococcal strains were grown at 30°C
in M17 medium (Merck GmbH, Darmstadt, Germany) supplemented
with D-glucose (0.5% [wt/vol]) (GM17), unless otherwise indicated. For
the cloning and propagation of constructs, Escherichia coli DH5 and
EC101 were used; they were grown aerobically at 37°C in Luria-Bertani
(LB) broth (21). Agar plates were prepared by adding 1.5% (wt/vol) agar
(Torlak, Belgrade, Serbia) to the liquid medium. Lactococcal transfor-
mants were selected on GM17 plates containing 10 g/ml erythromycin
(Sigma-Aldrich Chemie GmbH, Munich, Germany), while E. coli trans-
formants were selected on LB plates containing 300 g/ml erythromycin
or 100g/ml ampicillin, depending on the plasmids used. For blue/white
screening of colonies carrying vectors with cloned fragments, 5-bromo-
4-chloro-3-indolyl-D-galactoside (X-Gal) (Fermentas, Vilnius, Lithua-
nia) was added to LB plates at a final concentration of 50 g/ml.
Bacteriocin activity.The bacteriocin activity of tested strains andmu-
tants was analyzed by an agar well diffusion test (22). Bacteriocin extracts
were obtained after centrifugation (15,871  g for 10 min) of 16-h-old
cultures and subsequent filtration through filters with 0.45-m pores
(Sarstedt, Numbrecht, Germany). Lactococcus lactis subsp. lactisBGMN1-
596 was used as an indicator strain. Positive signals of bacteriocin activity
presented as clear zones of inhibition around the wells.
Whole-genome sequencing. DNA from strain LMG2081 was se-
quenced at the Norwegian Sequencing Centre (Oslo, Norway) using an
IlluminaMiSeq instrument, according to the manufacturer’s recommen-
dations. Approximately 1.5 million paired-end reads of 2 by 250 bp were
obtained. Using ABySS, a preliminary assembly of the LMG2081 genome
was obtained, with 100 contigs covering 2,548,962 bp.
Inverse PCR. The inverse PCR procedure was used to determine
neighboring contigs. The plasmid DNA of strain LMG2081 was digested
with EcoRI and then self-ligated to yield circularized fragments. The
ligation mixture was used as the template for PCR with the specific
primers LL and LD (Table 2). The PCR fragments obtained were pu-
rified and cloned into a commercial pGEM-T Easy vector to yield
pGEM-T EasyLL/LD, using E. coli DH5. The resulting products were
purified and sequenced.
Construction of mutants.Mutants for the bacteriocins lactococcin
G and lacticin LMG were constructed using the plasmid pGhost9
(carrying segments of the targeted genes), by insertion into operons.
The thermosensitive erythromycin-resistant plasmid pGhost9 was
TABLE 1 Bacterial strains and plasmids used in this study
Strain or plasmid Relevant characteristic(s) Source or reference
Lactococcus lactis strains
LMG2081 Bacteriocin (lactococcin G and lacticin LMG) producer 19
BGBM50 Lactococcin G producer 37
BGMN1-596 Plasmid-free derivate of L. lactis subsp. lactis BGMN1-5 35
LMG2081/pGhost9lcnG LcnG, LctLMG, LctLMGr This work
LMG2081/pGhost9lctLMG LcnG, LctLMG, LcnGr This work
Escherichia coli strains
DH5 80dlacZM15 (lacZYA-argF)U169 recA1 endA1 hsdR17(rK
mK
)
supE44 thi-1 gyrA relA1
38
EC101 JM101 containing repA gene of pWV01 in chromosome 39
DH5/pGEM-T EasylcnG This work
DH5/pGEM-T EasylctLMG This work
DH5/pGEM-T EasyLL/LD This work
EC101/pGhost9lcnG This work
EC101/pGhost9lctLMG This work
Plasmids
pGhost9 Emr; thermosensitive vector 40
pGhost9lcnG pGhost9 carrying fragment of lcnG gene This work
pGhost9lctLMG pGhost9 carrying fragment of lmgM gene This work
pGEM-T Easy 3,015 bp; Ampr; PCR cloning vector Promega
pGEM-T EasylcnG This work
pGEM-T EasylctLMG pGEM-T Easy carrying 814 bp of lmgM gene This work
ppGEM-T EasyLL/LD This work
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used to disrupt the lcnG and lmgM genes (24). PCR fragments of 378
bp and 814 bp, containing segments of the lcnG and lmgM genes,
respectively, were cloned into a pGEM-T Easy vector (Promega, Mad-
ison, WI, USA) to yield pGEM-T EasylcnG and pGEM-T EasylctLMG,
respectively. Then, fragments were subcloned into a pGhost9 vector
using the EcoRI restriction enzyme, resulting in the constructs
pGhost9lcnG and pGhost9lctLMG. These plasmid constructs were
introduced into L. lactis LMG2081 by electroporation. To enable integra-
tion of the constructs, the transformants obtained at 28°C were streaked
onto GM17 agar plates with erythromycin (10 g/ml) and incubated at
37°C for 48 h. Transformants containing the plasmids pGhost9lcnG and
pGhost9lctLMG integrated in the lcnG and lmgM genes, respectively,
were confirmed by their Bac phenotype, sensitivity to bacteriocin, and
pulsed-field gel electrophoresis (PFGE) and hybridization analysis results.
Southern blot hybridization was performed with a digoxigenin (DIG)
DNA labeling and detection kit (Roche Diagnostics GmbH, Germany),
following the manufacturer’s protocol, using an 814-bp fragment from
lmgM as a biotin-labeled probe.
Molecular methods. For clonal confirmation, PFGE was used (25).
For the isolation of total DNA from lactococci, a modified version (with
the addition of lysozyme treatment) of the method described by Hop-
wood et al. (26) was used, while the isolation of plasmid DNA from lac-
tococci was performed by the miniprep method described by O’Sullivan
and Klaenhammer (23). Plasmid DNA from E. coliwas isolated by using a
QIAprep spin miniprep kit (Qiagen, Hilden, Germany), according to the
manufacturer’s protocol. For DNA ligation, T4 DNA ligase (Agilent
Technologies, Santa Clara, CA, USA) was used, according to the man-
ufacturer’s instructions. Plasmid constructs were inserted in lacto-
cocci by electroporation using an Eporator (Eppendorf, Hamburg,
Germany) (27). For the amplification of DNA fragments by PCR using
a GeneAmp PCR System 2700 thermal cycler (Applied Biosystems,
Foster City, CA, USA), KapaTaq DNA polymerase (KapaBiosystem,
Inc., Boston, MA, USA) was used. A QIAquick gel extraction kit was
used for the purification of DNA fragments from agarose gels, accord-
ing to the manufacturer’s recommendations (Qiagen, Hilden, Ger-
many). For the purification of PCR products, a QIAquick PCR purifi-
cation kit (Qiagen) was used, according to the supplier’s protocol. For
the cloning of PCR products, the pGEM-T Easy (Promega) vector was
used. The purified PCR products obtained were sequenced by the
Macrogen Sequencing Service (Macrogen Europe, Amsterdam, The
Netherlands) and analyzed by using BLAST. The sets of specific prim-
ers used in this study are listed in Table 2. The functions of the proteins
encoded by the lctLMG operon were attributed on the basis of homol-
ogy with proteins determined by BLAST comparisons with the Entrez
protein database (Table 3). Sequence comparisons of LmgA and
representative lantibiotics forming the lacticin 481 group were per-
formed using Clustal Omega software (http://www.ebi.ac.uk/Tools
/msa/clustalo).
Purification andmass spectrometric analysis of bacteriocin lacticin
LMG. For the purification and mass spectrometric analysis of the bacte-
riocin lacticin LMG, a L. lactis LMG2081 lcnGmutant was grown at 30°C
for 16 h in 500 ml of GM17 broth, to the early stationary phase. The
removal of cells was performed by centrifugation (4,500 g for 30min at
4°C). The bacteriocin present in the supernatant was subjected to precip-
TABLE 2 Sequences of specific primers used in this study
Primer name Sequence of primer Gene Source or reference
LcnG-Fw 5=-GAAAGAATTATCAGAAAAAG-3= Lactococcin G gene 41
LcnG-Rev 5=-CCACTTATCTTTATTTCCCTCT-3= Lactococcin G gene 41
LctLMG-Fw 5=-TGCAGAAGTGGTTACGG-3= lmgM gene (position, bp 1095–1111) This work
LctLMG-Rev 5=-GGTTGAATAAGCAGGAG-3= lmgM gene (position, bp 1892–1908) This work
LL 5=-CCATTTTGCTAGTACAGTC-3= This work
LD 5=-GAACATAGTATGCAAAGGGG-3= This work
TABLE 3 Results of BLAST comparison of proteins encoded by lctLMG operon with Entrez protein database
ORF
No. of amino acids
(position)a
Protein with greatest homology
(accession no.)
Predicted domain(s) or
superfamily encoded by ORF Organism
Amino acid
identity (%)
lmgA 49 (bp 118–267) Lantibiotic nukacin (WP_037580734.1) Type A lantibiotic (pfam04604) Streptococcus equi 69
lmgA 49 (bp 118–267) Lantibiotic lacticin 481 (WP_032489363.1) Type A lantibiotic (pfam04604) Lactococcus lactis 73
lmgM 884 (bp 757–3411) Lacticin 481/lactococcin biosynthesis
protein LcnDR2 (WP_032489360.1)
Lantibiotic-modifying enzyme
(COG4403), cyclases involved
in biosynthesis of class II
lantibiotics (cd04792)
Lactococcus lactis 45
lmgT 696 (bp 3420–5510) Lacticin 481/lactococcin DR transport/
processing ATP-binding protein
LcnDR3 (WP_032489362.1)
Peptidase C39 family
(pfam03412)
Lactococcus lactis 53
lmgF 303 (bp 5587–6498) Bacitracin transport ATP-binding protein
BcrA (CIT27467.1)
ATP-binding cassette domain of
bacitracin-resistance
transporter (cd03268)
Streptococcus pneumoniae 65
lmgE 250 (bp 6498–7250) NukE (AKQ51582.1) ABC-2 family transporter protein
(pfam12730), lantibiotic
protection ABC transporter
permease subunit (TIGR03733)
Staphylococcus epidermidis 48
lmgG 245 (bp 7247–7984) NukG (AKQ51591.1) Predicted lantibiotic-exporting
membrane permease,
EfiE/EfiG/ABC2 family
(COG4200)
Staphylococcus epidermidis 49
a The number of amino acids and the position of the lctLMG operon from the beginning of the sequence are given for each ORF.
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itation with ammonium sulfate at 40% (wt/vol) saturation, with stirring,
for 3 h at 4°C. The precipitate was collected by centrifugation (10,000 g
for 30 min at 4°C) and then dissolved in 5 ml of Milli-Q water containing
0.1% trifluoroacetic acid. The bacteriocin was purified using reverse-
phase high-performance liquid chromatography (HPLC). Reverse-phase
chromatography of the bacteriocin sample was performed using an Äkta
Purifier 10 system (GE Healthcare, Uppsala, Sweden) with a Discovery
BIOWide PoreC5 column (10 cmby 4.6mm; particle size, 5m; Supelco,
Bellefonte, PA, USA). The protein was eluted using an acetonitrile gradi-
ent (0 to 90% with 0.1% trifluoroacetic acid for 10 column volumes). The
chromatography was monitored by measuring absorbance at 215 nm. The
protein fractionsobtainedweredriedunder a streamofnitrogen, dissolved in
the same volume ofMilli-Q water, and tested for antibacterial activity.
Mass spectrometric analysis.Mass analysis of the isolated bacteriocin
was carried out using a mass spectrometer coupled with HPLC. The sam-
ple was injected onto a reverse-phase C18 column (RRHT column; 4.6 by
50 mm; particle size, 1.8 m) coupled with a Zorbax Eclipse XDB-C18
column installed in a 1200 series HPLC system (Agilent Technologies).
The sample components were separated using an acetonitrile gradient (5
to 95% with 0.2% formic acid for 10 min and then 95% for 5 min). The
mass spectrometer, a 6210 TOF liquid chromatography-mass spectrometry
(LC-MS) system(G1969A;AgilentTechnologies, SantaClara,CA,USA),was
run in positive ESI mode with a capillary voltage of 4,000 V, a fragmentor
voltage of 200 V, and a mass range ofm/z 100 to 3,200. Agilent MassHunter
Workstation software and Analyst QS were used for data processing.
Nucleotide sequence accession number. The DNA sequence pre-
sented in this article has been deposited in the European Nucleotide Ar-
chive (ENA) and GenBank databases, under accession no. LN879392.
RESULTS
Genome sequencing results. In a bacteriocin assay, we observed
that the lactococcin G producer L. lactis LMG2081 killed not only
the L. lactis subsp. lactis BGMN1-596 indicator strain but also L.
lactis subsp. lactis BGBM50, another lactococcin G producer. This
indicated that LMG2081 produces one or more bacteriocins that
are not present in BGBM50 (Fig. 1A and B).
To search for additional bacteriocins, we performed genome
sequencing of LMG2081. An incomplete bacteriocin-like operon
was identified at the end of one contig. By primer walking, the
entire operon was revealed in an 8-kb fragment. The operon,
called lctLMG, contains six open reading frames (ORFs), named
lmgA, lmgM, lmgT, lmgF, lmgE, and lmgG (Fig. 2; Table 3). In silico
analysis of the surrounding sequences of lctLMG revealed a down-
streamORF encoding a Pin-related site recombinase/DNA inver-
tase with the greatest amino acid identity (83%) with the Pin-
related site recombinase/DNA invertase from L. lactis (GenBank
accession no. WP_046782557.1). The flanking DNA sequence
from the upstream region is currently unavailable. The lmgA gene
appears to be a structural gene encoding a 49-amino-acid precur-
sor peptide that is expected to be cleaved between alanine and
glycine following posttranslational modifications, to form a
25-residue mature peptide. We derived a consensus sequence
of lacticin 481-like bacteriocins based on invariant residues in a
protein sequence comparison of representative lantibiotics
forming the lacticin 481 group and LmgA (Fig. 3). The N-ter-
minal extremities, or leader peptides, of the peptides analyzed
were variable in length and sequence but contained three in-
variant residues. The propeptides of the lantibiotics compared
were more conserved than the leader peptides, and we found 12
invariant residues in the propeptides. The C termini of these
propeptides corresponded to invariant regions of four amino
acids (TCCS). In addition to invariant residues, we found four
conserved residues in the leader peptides and seven conserved
residues in the propeptides (Fig. 3).
In the region downstream of the lmgA gene, anORFwas found
and designated lmgM (2,654 bp). The product of lmgM is likely a
modification enzyme involved in the biosynthesis of the lantibi-
otic lacticin LMG (Table 3) (28, 29). Moreover, lmgT (2,090 bp)
presumably codes for the ABC-containing maturation and secre-
tion (AMS) protein, which cleaves off the leader peptide and se-
cretes the mature lantibiotic (Table 3) (30, 31). At the end of the
operon, three genes, i.e., lmgF (911 bp), lmgE (752 bp), and lmgG
(737 bp), likely code for proteins similar to the ABC transporter
and provide immunity by ejecting the lantibiotic from the mem-
brane (Table 3). Similar immunity systems are present for the
lantibiotics lacticin 481, mutacin II, and streptococcin SA-FF22;
in each case, a systemof three genes, lanF, lanE, and lanG, provides
immunity against lantibiotics (32). In the case of the lantibiotic
nukacin ISK-1, the presence of two immunity systems, NukFEG
and NukH, provides a much higher level of immunity than each
system alone (9).
Construction of mutant strains. To check the functionality
of bacteriocin operons in strain LMG2081, insertional mu-
FIG 1 Analysis of the bacteriocin activity of L. lactis LMG2081 and itsmutants. (A) LMG2081 against BGMN1-596. (B) LMG2081 against BGBM50 (lactococcin
G producer). (C) LMG2081/pGhost9lcnG (lcnG) against BGMN1-596. (D) LMG2081/pGhost9lctLMG (lcnLMG) against BGBM50. (E) LMG2081/
pGhost9lctLMG against BGMN1-596.
FIG 2 Linear genemap of the region carrying the 8,000-bp lctLMG operon in L. lactis LMG2981. The positions of relevant restriction sites are indicated. Arrows,
size and orientation of predicted ORFs.
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tagenesis of structural genes for the bacteriocins lactococcin G
and lacticin LMG was performed separately. Plasmid con-
structs (pGhost9lcnG and pGhost9lctLMG) were integrated
into the corresponding genes lcnG and lmgM, yielding two differ-
ent mutants, i.e., LMG2081/pGhost9lcnG (minus lactococcin
G) and LMG2081/pGhost9lctLMG (minus lacticin LMG), re-
spectively. Transformants of L. lactis LMG2081 were grown at
37°C for 48 h and were analyzed by Bac phenotype analysis,
PFGE, and hybridization. The mutants with an integrated
pGhost9lcnG plasmid construct in the lcnG gene showed lower
activity against the L. lactis subsp. lactis BGMN1-596 indicator
strain than did the wild-type (WT) LMG2081 strain (Fig. 1A and
C). The second group of mutants, which had an integrated
pGhost9lctLMG plasmid construct in the lmgM gene, lost inhi-
bition activity against L. lactis subsp. lactis BGBM50 (lactococcin
G producer) (Fig. 1D) and showed significantly lower activity
against BGBMN1-596 (Fig. 1E). The high antimicrobial activity of
strain LMG2081 is the result of the additive effects of the bacterio-
cins lactococcin G and lacticin LMG. The bacteriocin activity of
the constructedmutants confirmed that strain LMG2081 contains
two functional bacteriocin operons. The antimicrobial activities
of the WT strain and both mutants were tested against various
pathogenic or nonpathogenic bacteria. The WT strain and mu-
tants producing lacticin LMG or lactococcin G showed activity
only against lactococci.
Localization of lacticin LMG operon. PFGE together with
Southern blot hybridization was used for localization of the lacti-
cin LMG and lactococcin G operons in the L. lactis LMG2081
strain. For that purpose, total DNA of the WT strain and the two
mutants (with a disrupted lacticin LMG operon [LMG2081/
pGhost9lctLMG] or lactococcin G operon [LMG2081/
pGhost9lcnG]) that had been digested with NotI or SmaI, not
digested, or treated with S1 nuclease was used. Bacteriocin mu-
tants of strain LMG2081 were made by integration of a
pGhost9 plasmid carrying NotI and SmaI sites, which are
introduced into given operons by plasmid integration. The re-
sults of PFGE-hybridization experiments confirmed that the
lctLMG operon is located on a plasmid of approximately 115 kb
that does not possess NotI and SmaI restriction sites (Fig. 4A
and B, lanes 2 and 6). In addition, when nondigested DNA and
S1 nuclease-treated DNA from LMG2081 and the mutants
were analyzed by PFGE and hybridization, signals from the
lacticin LMG (lmgM) probe were obtained only with extrach-
romosomal bands (Fig. 4B, lanes 12 to 14) that are positioned
on the gel in the region of approximately 115 kb, very similar to
the findings obtained with linearized plasmids. In contrast, the
FIG 3 Alignment of the deduced peptide sequence for lacticin LMG and homologous type A(II) lantibiotics, including nukacin ISK-1 from Staphylococcus
warneri (GenBank accession no. Q9KWM4), lacticin 481 from Lactococcus lactis (GenBank accession no. WP_032489363), variacin from Kocuria varians
(GenBank accession no. CAA63706), butyrivibriocin OR79 from Butyrivibrio fibrisolvens (GenBank accession no. AAC19355), lacticin LmgA from Lactococcus
lactis (GenBank accession no. CUH82811.1), and salivaricin G32 from Streptococcus salivarius (GenBank accession no. AFB74480). Underlined amino acids,
leader peptide; x, undefined residues. Gray shading and asterisks indicate identical amino acids, periods indicate amino acids belonging to similar groups, and
colons indicate amino acids belonging to the same group.
FIG 4 PFGE profiles of Lactococcus lactis LMG2081 and lacticin LMG and lactococcin G mutants (A) and Southern blot hybridization with a lmgM probe (B).
Total DNA from Lactococcus lactis LMG2081 (lanes 1, 5, 8, and 12), LMG2081/pGhost9lctLMG (lanes 2, 6, 9, and 13), or LMG2081/pGhost9lcnG (lanes 3, 7,
10, and 14) was digested with NotI (lanes 1 to 3) or SmaI (lanes 5 to 7), not digested (lanes 8 to 10), or treated with S1 nuclease (lanes 12 to 14). Lanes 4 and 11,
 concatemers. White arrows, linearized plasmids carrying the lctLMG operon; black arrows, differences in chromosomal fragments between theWT strain and
the lactococcin G mutant.
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lactococcin G operon is chromosomally located on a NotI frag-
ment of 380 kb. Integration of pGhost9 into the lactococcin G
operon split this fragment into fragments of 310 and 70 kb (Fig.
4A, lane 3).
Mass spectrometry. A novel active lacticin LMG was purified
to homogeneity by ammonium sulfate precipitation and reverse-
phase chromatography. The active fraction was spotted on GM17
soft agar that had been inoculated with L. lactis subsp. lactis
BGBM50, for 24 h at 30°C (Fig. 5A). The molecular mass deter-
mined for the active fraction by ESI-TOF mass spectrometry was
2,759 Da (Fig. 5B). The mass analysis showed that the recorded
molecular ions of the active fraction werem/z 2,760 ([MH]),
2,782 ([MNa]), and 2,798 ([M K]). Based on amino acid
sequence analysis, cleavage of the leader peptide occurred between
amino acids Ala23 and Gly24 to form a 25-residue excreted pep-
tidewith a calculatedmolecularmass of 2,831Da. Considering the
high degree of conservation of important amino acid residues be-
tween lacticin LMG and lacticin 481-type lantibiotics, it could be
assumed that lacticin LMG underwent the same types of post-
translational modifications as its homologue lacticin 481. Lacticin
481-type lantibiotics contain threonine, serine, and cysteine,
which tend to be converted to unusual amino acids such as dehy-
drobutyrine, lanthionine, and 3-methyllanthionine, followed by
the elimination of one water molecule. Therefore, the positions of
the thioether bridges were predicted to be between residues 7 and
12, 9 and 23, and 16 and 24, while the position of dehydrobutyrine
was predicted to be at residue 22. According to the proposed post-
translational modifications, the calculated molecular mass of ma-
ture lacticin LMGwas 2,759Da, exactly the same as determined by
mass spectrometry.
DISCUSSION
In this study, we provide strong evidence that lacticin LMG is a
novel lantibiotic produced by L. lactis strain LMG2081. The
lctLMG operon showed organization similar to that of the other
operons of the lacticin 481 group. Downstream of the operon, we
identified an ORF encoding a Pin-related site recombinase/DNA
invertase, indicating the end of the lctLMG operon. However, the
sequence upstream of the lmgA gene is presently not available;
therefore, whether there are additional genes involved in the syn-
thesis or regulation of expression of lacticin LMG is not known.
Analysis of the lctLMG operon sequence showed that lacticin
LMGwas synthesized as a 49-amino-acid precursor peptide, sim-
ilar to lacticin 481-type lantibiotics. The amino acid sequences of
the propeptide of lacticin LMG and the leader peptide show dif-
ferent levels of identity with those of lacticin 481 and other repre-
sentative lacticin 481-like lantibiotics (Fig. 3). The propeptide of
lacticin LMG shares 76% and 74% identity with lacticin 481 and
nukacin ISK-1, respectively, while the leader sequence of lacticin
LMG shares 76% identity with lacticin 481 and 50% identity with
nukacin ISK-1. The mature lacticin LMG is shorter by two amino
acids at its amino-terminal end and has six conservative amino
acid substitutions in comparison with lacticin 481 and seven sub-
stitutions in comparison with nukacin ISK-1. Furthermore, in
lacticin LMG, three cysteine residues, two threonine residues, and
a Ser-9 residue involved in lanthionine ring formation were con-
served, while Ser-18 was replaced by a Thr-16, also dehydrated. In
the case of streptococcin SA-FF22, the formation of thioether
bonds between Cys and dehydrated Thr-18 results in 3-methyl-
lanthionine (Abu-S-Ala, in which Abu is an aminobutyric acid
and Ala is alanine) (33). Consequently, streptococcin SA-F22 in-
cludes one lanthionine (Ala-S-Ala) and two 3-methyllanthionines
instead of two lanthionines and one 3-methyllanthionine, but it
has the same bridging pattern as lacticin 481 and nukacin ISK-1
(34). Based on these results, we assume that the same posttransla-
tional modifications occur in the case of lacticin LMG.
The proteolytic cleavage site of the leader peptide in the lacticin
LMG precursor peptide is predicted to be between Ala and Gly,
yielding a 25-amino-acid mature lantibiotic peptide. This is in
contrast to all other known lantibiotic peptides, which contain 27
amino acid residues. Using this theory, the calculated molecular
mass of the active lacticin LMG is 2,759 Da, which is in agreement
with the molecular mass determined by ESI-TOFmass spectrom-
etry (100% match). Although lacticin LMG shares a high level of
identity with the previously described lacticins (lacticin 481 and
nukacin ISK-1), this novel lantibiotic has specific features that
make it unique, such as its molecular weight, amino acid substi-
tutions, and operon structure. It is known that lactococci can syn-
thesizemore than one bacteriocin, such as in strainsL. lactis subsp.
cremoris 9B4 and L. lactis subsp. lactis BGMN1-5, which produce
at least three different bacteriocins (35, 36) despite belonging to
the same group (class II). In the present study, the lactococcal
strain LMG2081 has been shown to produce two bacteriocins be-
longing to different groups, one in class I (lantibiotics; lacticin
LMG) and the other in class IIb (lactococcinG). In addition, oper-
ons encoding lacticin LMG and lactococcin G are located on dif-
FIG 5 Bioassay for the production of lacticin LMG in L. lactis LMG2081 and
mass spectrometric analysis. (A) Reverse-phase HPLC. The active fraction was
spotted onGM17 soft agar that had been inoculatedwith the indicator strain L.
lactis subsp. lactis BGBM50. (B) Calculated molecular mass of lacticin LMG,
determined by ESI-TOF mass spectrometry.
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ferent genetic elements, i.e., on a plasmid and the chromosome,
respectively.
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